Keywords: neutec, reports, progress, ph, ii, trial, aurograb

NeuTec reports progress in Ph II trial of Aurograb for MRSA infections

Article | 20 January 2003

Print This

Manchester, UK-based NeuTec Pharma has completed a Phase IIadose-ranging study of Aurograb, an antibody for the treatment of the serious ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in